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Cell cycleCaMKs link transient increases in intracellular Ca2+with biological processes. In myeloid leukemia cells, CaMKII,
activated by the bcr-abl oncogene, promotes cell proliferation. Inhibition of CaMKII activity restricts cell prolifer-
ation, and correlates with growth arrest and differentiation. The mechanism by which the inhibition of CaMKII
results in growth arrest and differentiation in myeloid leukemia cells is still unknown. We report that inhibition
of CaMKII activity results in an upregulation of CaMKIV mRNA and protein in leukemia cell lines. Conversely,
expression of CaMKIV inhibits autophosphorylation and activation of CaMKII, and elicits G0/G1cell cycle arrest,
impairing cell proliferation. Furthermore, U937 cells expressing CaMKIV show elevated levels of Cdk inhibitors
p27kip1 and p16ink4a and reduced levels of cyclins A, B1 and D1.
These ﬁndings were also conﬁrmed in the K562 leukemic cell line.
The relationship between CaMKII and CaMKIV is also observed in primary acute myeloid leukemia (AML) cells,
and it correlates with their immunophenotypic proﬁle. Indeed, immature MO/M1 AML showed increased
CaMKIV expression and decreased pCaMKII, whereas highly differentiated M4/M5 AML showed decreased
CaMKIV expression and increased pCaMKII levels.
Our data reveal a novel cross-talk between CaMKII and CaMKIV and suggest that CaMKII suppresses the expres-
sion of CaMKIV to promote leukemia cell proliferation.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).1. Introduction
Multifunctional CaMKs (CaMKI, CaMKII and CaMKIV) are important
mediators of intracellular Ca2+ signalling that play pleiotropic roles in
cell physiology. These serine–threonine (Ser/Thr) protein kinases aredulin dependent kinase; RAR,
itor; AML, acutemyeloid leuke-
r), illario@unina.it (M. Illario).
urosciences (IZN), Ruprecht
. This is an open access article underactivated upon Ca2+/CaM binding. The upstream CaMK kinases
(CaMKKs) phosphorylate a critical Thr 200 in the activation-loop to acti-
vate CaMKIV, whereas CaMKII is fully activated by autophosphorylation
of its own Thr 286 [1,2]. Ca2+/CaM signaling is necessary for cell cycle
progression, and CaM-dependent pathways inﬂuence cyclin-Cdk activa-
tion at different phases of the cell cycle [3]. Several studies suggest the in-
volvement of CaMKs at G1/S and G2/M transitions of the cell cycle [4–8].
Furthermore, treatment of several cell types with KN93, a pharmacologi-
cal inhibitor of CaMKs, elicits a reversibleG1 arrest that correlateswith en-
hanced association of p27kip1 with Cdk2 and reduced Cdk2/4 activity [9].
CaMKIV is a predominantly nuclear, monomeric kinase with tissue-
restricted expression [1]. It plays a role in mediating Ca2+-regulated
transcription through phosphorylation and/or activation of different
transcription factors, including cyclic adenosine mono phosphatethe CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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scription factor (ATF), serum response factor (SRF), and transcrip-
tional co-factors including CREB binding protein (CBP) [10].
Embryonic expression of CaMKIV correlates with periods of differen-
tiation and terminal mitoses, supporting for this kinase a pivotal role
in regulation of cell differentiation [11]. Indeed, in hematopoietic
stem cells (HSCs), CaMKIV/CREB/CBP pathway restricts cell prolifer-
ation by expression of Bcl-2, a pro-survival protein with additional
roles in cell quiescence [12]. In cancer cells, CaMKs appear to play a
role in aggressiveness: CaMKK2 signaling through adenosine
monophosphate dependent protein kinase (AMPK) [13] and/or
CaMKI [3] modulates cell migration, invasiveness and malignancy
in prostate cancer and medulloblastoma [14,15]. Notably, CaMKIV
is not expressed in these two cancer cell types, a feature that the au-
thors attributed to reduced expression of genes required for differ-
entiation [14].
The ubiquitously expressed, multimeric CaMKII is predomi-
nantly cytoplasmic, although 3 alternatively spliced variants:
αB,γA, and δB are targeted to the nucleus [16,17]. CaMKII exerts a
broad range of biological functions, and is an important regulator
of cell proliferation [18,19]. It modulates Raf1 activity leading to
extra-cellular receptor kinase (ERK) activation and induction of
cell proliferation. The interplay between CaMKII and ERK has
been observed in several cell types including thyroid [20,21], ﬁbro-
blasts [22], skeletal muscle [23] and vascular smooth muscle [24],
suggesting that it is a general mechanism in the control of cell pro-
liferation. CaMKII is also a target of RET-PTC oncogene, raising the
possibility that it plays a central role in the abnormal growth of
tumor cells [25].
Many studies suggest the involvement of CaMKII in the homeostasis
of tumor cells. Indeed, Si and Collins reported thatmyeloid leukemia cell
lines as well as primary acute myeloid leukemia (AML) patient samples
express elevated levels of activated CaMKII. CaMKII promotes G1/S cell
cycle progression [26] and its inhibition impairs myeloid leukemia cell
proliferation. Leukemia cells undergoing growth arrest and/or terminal
differentiation presentmarkedly reduced levels of CaMKII [26], suggest-
ing that downregulation of CaMKII may be a pre-requisite for inducing
terminal differentiation in myeloid leukemia cells.
Because of the reciprocal aspects of CaMKII and CaMKIV on prolifer-
ation [12] and terminal differentiation [11,27,28] in hematopoietic pro-
genitors, we hypothesized that CaMKIV may be repressed in a CaMKII
dependent manner in myeloid leukemia cells. In the present study,
we investigated a potential cross-talk between CaMKII and CaMKIV
in human myeloid leukemia U937 cells [29], which express very low
CaMKIV and high CaMKII levels. We found that CaMKII represses
CaMK4 transcription and promotes proliferation in human myeloid
leukemia cells. On the other hand, transgenic enhanced expression of
CaMKIV negatively modulates CaMKII activity and induces G0/G1 cell
cycle arrest in these malignant cells. We propose that CaMKII and
CaMKIV counterregulation is not restricted to leukemia cells and can
be exploited in the development of targeted therapies against myeloid
leukemia and other myeloid disorders.2. Materials and methods
2.1. Cell culture and reagents
U937 andK562 (CRL1593.2 and CCl243, respectively, American Type
Culture Collection (ATCC), Manassas, VA) were cultured in RPMI-1640
Medium (Invitrogen, Carlsbad, CA) supplementedwith 10% fetal bovine
serum (FBS; Invitrogen). Human embryonic kidney HEK 293A cells
(R70507, Invitrogen) were grown in DMEM supplemented with 10%
FBS (Invitrogen). Cells were stimulated with 2 μM ionomycin (Sigma,
St. Louis, MO) for 15 min or with 10% FBS following 12 h serum starva-
tion. CaMKII pharmacological inhibitionwas obtainedwith 10 μMof theCaMKs inhibitor KN93 (Biomol PlymouthMeeting, PA); or with 5 μMof
the CaMKII selective inhibitory peptide, AntCaNtide [30].
2.2. RNA interference
Four CaMKIIγ-speciﬁc shRNA (SureSilencing shRNA plasmids) and
control shRNA vector were purchased from SuperArray. The targeted se-
quences are shRNA1: ACCTGCTGCTGGCGAGTAAAT; shRNA2;GAACGTGA
GGCTCGGATATGT; shRNA3: GAGGCCTACACGAAGATTTGT; shRNA-4:
GAGTGTTTGCGCAAGTTCAAT. CaMKIIγ-shRNA design was based on the
GenBank accession number NM_001222. CaMKIIγ- shRNA transfections
were performed using Attractene Transfection Reagent.
These four plasmids were, ﬁrst, transiently transfected in U937 cells
according to themanufacturer's instructions, and then selected in G418
(800 μg/mL) for 10 d. We ﬁrst indentiﬁed one shRNA that caused N80%
reduction in the endogenous CaMKIIγ levels.
2.3. Lentiviral infection
Lentivirus-green ﬂuorescent protein (GFP) constructs were generat-
ed and characterized as mentioned before [31]. Brieﬂy, full-length WT
CaMKIVcDNA (a gift from Dr. Anthony R. Means, Duke University Med-
ical Center) was cloned into a Lenti-green ﬂuorescent protein (GFP)
vector [32]. Empty Lenti-GFP-control (“Mock”), Lenti-GFP-CaMKIV
(“CaMKIV”) and Lenti-GFP-CaMKIV-K71M viruses were generated as
previously described [3,4] using second generation helper plasmids in
293T cells (a gift from Dr. Anthony R. Means, Duke University Medical
Center and described in Kitsos et al. [12]). Virus titers were calculated
using 293T cells and CaMKIV expression conﬁrmed by immunoblotting.
Approximately 2 × 106 of U937 cells were infected with control (Mock)
or Lenti-GFP-CaMKIV (CaMKIV) viruses at a multiplicity of infection
of 10:1.
2.4. Cell viability and [3H] thymidine (T) incorporation assays
50,000 cells/well were counted daily following trypan blue staining
(Invitrogen). 5000 cells were serum-starved for 12 h, and DMEM-10%
FBS with 0.5 μCi [3H] thymidine (T) and CaMKII inhibitors were added.
After 24 h, [3H] T uptake was evaluated (BD Biosciences, San Jose, CA).
2.5. Cell cycle distribution assay
Cells were ﬁxed in 70% ethanol, incubated with 0.02 mg/ml
propidium iodide (PI) and 0.25 mg/ml ribonuclease A (Sigma), and
analyzed for DNA content (FACScan, BD). Acquisition and analyses
were performed using CellQuest (BD) software.
2.6. Annexin V apoptosis assay
3 × 106cells were incubated with AnnexinV-PE and PI
(BDPharmingen, USA) and analyzed by ﬂow cytometry. Samples
were acquired with a CYAN ﬂow cytometer (DAKO Corporation,
San Jose, CA) and analyzed using SUMMIT® software.
2.7. Ki-67 staining
Cells were incubated with Ki-67-PE antibody and 7-amino actino-
mycin D (7AAD, BD) and analyzed (FACSAria, BD).
2.8. Bromo deoxy uridine (BrdU) labeling
Cells were pulse-labeled with 10 μM BrdU (Sigma). Samples
were processed and incubated with BrdU-PE antibody and 7AAD (BD),
and analyzed on a FACSAria.
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HEK 293A cells were transiently transfected with 0.1 μg of renilla
luciferase pRLTK vector and 1 μg each of ﬁre ﬂy luciferase reporter con-
struct containing a CaMK4 promoter harboring RARβ response elements
(RRE) [33], expression constructs encoding RAR-β, chicken ovalbumin
upstream promoter transcription factor (COUP-TF) and CaMKII. Two
days later, transfected cells were treated with 2 μM retinoic acid
(Sigma) for 2 h and assayed using a dual Luciferase Assay Reporter Sys-
tem Kit (Promega Co., Madison, WI).
2.10. CaMKII activity assays
Endogenous CaMKII was immunoprecipitated with 5 μL of anti-
CaMKII antibody and 25 μL of protein G plus/protein A agarose beads/
1 mg total cell extract (Santa Cruz, CA). CaMKII was incubated for
30 min at 30 °C with 1 mM CaCl2 and 1 μM CaM in 50 μl of reaction
mixture (50 mM HEPES pH 7.5, 10 mM MgCl2, 0.5 mM dithiothreitol
(DTT), 100 nM microcystin, 0.1 mM cold ATP). In a second reaction
step, an aliquot from the ﬁrst reaction was incubated with the CaMKII
substrate Autocamtide and [32P]-γATP (GE-Amersham, Piscataway,
NJ); EGTA was added to quantify CaMKII autonomous activity.
2.11. Quantitative reverse transcription polymerase chain reaction
(qRT-PCR)
Total RNA was extracted with a RNA 4-PCR kit (Applied Biosystems,
Foster City, CA) and reverse transcribed using a High Capacity Reverse
Transcriptase Kit (Applied Biosystems). QRT-PCR was performed by
Bio-Rad IC5 thermo-cycler (Bio-Rad Laboratories, Hercules, CA).
Primers sequences used for hCaMKIV are: 5′-GGC ACA GGC TGA GCT
GAT G-3′ forward and 5′-CTA GTT CCA GGT CAG CCA CCT TT-3′ reverse
primers. Cycle threshold (Ct) values from 3 independent experiments
were normalized to the internal β-actin control. The ratio of fold change
was calculated using the Pfafﬂmethod [34].
2.12. Patient specimen collection
AML specimens were obtained from peripheral blood or bone mar-
row of patients following informed consent at the time of diagnostic bi-
opsy. Weekly calibration using beads (Beckman Coulter Inc. Brea, CA)
was performed. Whole BM samples in EDTA were washed 3 times in
phosphate-buffered saline (PBS) and resuspended with 1% bovine
serumalbumin in PBS. 100 μLwere incubatedwith each of the following
titered monoclonal antibodies (MoAbs) for 15 min: 5 μL HLA-DR FITC,
5 μL Myeloperoxidase FITC, 5 μL CD2-PeCy7, 5 μL CD3 PE, 5 μL CD4 PE,
5 μL CD5-PeCy7, 5 μL CD8-PeCy5, 5 μL CD7 FITC, 5 μL CD10 PE, 5 μL
CD11a FITC, 5 μL CD11b-PeCy5, 5 μL CD11c PE, 5 μL CD13-PeCy5, 5 μL
CD14 FITC, 5 μL CD15 FITC, 5 μL CD19 PeCy5, 5 μL CD20 PE, 5 μL CD24
PE, 5 μL CD25 FITC, 5 μL CD33 PeCy5, 5 μL CD34 PeCy7, 5 μL CD45RO
PE, 5 μL CD45RA PE (Beckman Coulter Inc. Brea, CA). Erythrocytes
were lysed by BD FACS lysing solution. Cells were pelleted (416 g for 5
min), washed and resuspended in 0.5 mL of 1% of paraformaldehyde.
160,000 to 1,000,000 total BM cells were acquired/sample. Based on
FAB/WHO immunologic criteria, 4 cases with the immunophenotype
MPO+/−, CD13+/, CD33+/−, CD34+/−, CD117+, HLA-DR+/−
were classiﬁed as M0/M1 AML, 2 cases MPO+, CD13+, CD15+,
CD19+, CD33+, CD34+, CD56+, CD117+/−, HLA-DR + as M2
AML, 1 case MPO+, CD13+, CD14+/−, CD15−, CD33+, CD34−,
CD56−, CD64+, CD117−/+, HLA-DR- as AML M3, 6 cases MPO+,
CD2+, CD13+, CD14+/−, CD15+/−, CD33+, CD34−/+, CD64+,
CD117+, HLA-DR + as M4 AML, 7 cases MPO−/+, CD13+,
CD14+/−, CD33+, CD34−, CD64+, CD117+/−, HLA-DR + as AML
M5, 1 case MP0-, CD13+/−, CD14+/−, CD33+/−, CD34−, CD61+,
CD117−, HLA-DR+/− as M7 AML.Small samples of normal bonemarrowwere collected from the sack
left following transplant.
2.13. Flow cytometry on primary human cells
Bonemarrow aspirate specimens were tested on a dual laser system
Beckman Coulter, Cytomics FC500 (Beckman Coulter Inc. Brea, CA)
using CXP software (see SM).
2.14. Statistical analysis
Student's t-test was used for statistical signiﬁcance; a p-value b 0.05
was deemed signiﬁcant.
3. Results
3.1. Inhibition of CaMKII activity elevates CaMKIV expression
Pharmacological inhibition of CaMKII activity induces cell cycle
arrest in several cell types including myeloid leukemia cells [5,7,26].
To identify the underlying mechanism of growth inhibition, U937 cells
were treated with 10 μM KN93. Whereas the levels of total CaMKII
did not change, autophosphorylation of CaMKII became signiﬁcantly
reduced within 6 h of KN93 treatment, and completely repressed after
24 h (p-CaMKII, Fig. 1A). In contrast to CaMKII, which is abundantly
expressed in U937 myeloid leukemia cells, expression of CaMKIV
is very low (Fig. 1A and Supplementary Fig. S1). However, levels of
CaMKIV increased as a function of time in U937 cells following exposure
to KN93 (Fig. 1A). This result was reproduced also in K562 cells,
conﬁrming that this mechanism is not restricted to U937 cells (Fig. 1F).
To understand whether CaMKIV increase occurs at the transcriptional
level, we analyzed CaMK4mRNA in U937 cells treated with KN93. As in-
dicated in Fig. 1B, CaMK4mRNA levels increase by 24h and becomemax-
imally up-regulated by 72 h after KN93 treatment, indicating that
CaMKIV increase following CaMKII inhibition involves enhanced Camk4
transcription. To further conﬁrm the effect of CaMKII inhibition on
CaMKIV expression, we analyzed CaMK4 mRNA and protein levels in
U937 cells following treatment with the CaMKII-speciﬁc inhibitory pep-
tide, AntCaNtide [21–23,30]. Accordingly, antCaNtide treatment resulted
in a time-dependent increase of CaMKIV protein levels (Fig. 1C). Inhibi-
tion of CaMKII activity using AntCaNtide also resulted in a signiﬁcant
induction of CaMK4 mRNA within 6 h (Fig. 1D). Altogether, these data
suggest that inhibition of CaMKII promotes CaMK4 mRNA synthesis.
Since CaMKIIγ is the predominantly expressed isoform of CaMKII in
bothmyeloid cells and U937 [35,36], we also determined the effect of si-
lencing CaMKIIγ by shRNA on CaMKIV expression in this latter cell line.
As shown in Fig. 1E, CaMKIIγ shRNA inU937 cells increased CaMKIV pro-
tein expression in a similar way of KN-93 and AntCaNtide treatments.
This result is consistentwith CaMKIV upregulation after pharmacological
inhibition of CaMKII.
It is known that CaMKII directly binds to and phosphorylates the
nuclear hormone receptor transcription factor RAR [35]. In myeloid
cells, this phosphorylation results in enhanced binding of RAR to tran-
scriptional co-repressors, inhibiting RAR-mediated transcription from
target genes. The 5′ ﬂanking region of human CaMK4 promoter contains
RAR response elements (RRE) and treatmentwith retinoic acid (RA) re-
sults in transactivation of the CaMK4 promoter through the RRE [33]. In
fact, RAR acts in concert with chicken ovalbumin upstream promoter
transcription factor (COUP-TF) at the RRE elements on CaMK4 promot-
er. Indeed, in embryonic stem (ES) cells differentiated into neurons, en-
dogenous CaMKIV is regulated by T3, and a single complex element in
the rat CaMKIV 5′-ﬂanking region confers this regulation. The isolated
element is also stimulated by RA. COUP-TF1, which suppresses the T3
response and augments the RA response in vitro, binds to an overlap-
ping sequence in the same site [33]. We surmised that in proliferating
leukemia cells, CaMKII could mediate repression of RAR-mediated
Fig. 1. Pharmacological inhibition of CaMKII induces the expression of CaMKIV. A) KN93-mediated inhibition of CaMKII activity results in the elevation of CaMKIV protein. Representative
immunoblots showing levels of CaMKIV, pT286CaMKII (p-CaMKII), total CaMKII and Actin (loading control) in U937 cells treated with 10 μM KN93 for indicated time points (n = 3).
B) Inhibition of CaMKII by KN93 results in the upregulation of CaMK4mRNA. Average CaMK4mRNA levels, normalized to internal control β-Actin, in U937 cells at 0, 6, 12, 24, 48 and
72 h after treatmentwith 10 μMKN93 from three experiments are shown. Data are indicated as fold induction over untreated (0 h time point); error bars represent ± standard deviation
(SD); *p-value b 0.05. C) Inhibition of CaMKII activity using the highly speciﬁc inhibitory peptide AntCaNtide results in highly increased CaMKIV protein level. Immunoblots depicting
CaMKIV and Actin in U937 cells treatedwith 5 μMAntCaNtide for the indicated time points (n= 3). D) Treatment of U937 cells with 5 μMAntCaNtide results in a signiﬁcant upregulation
of CaMK4mRNA from 6 h to 72 h. Average ± SD CaMK4mRNA levels (normalized to β-Actin), measured by qRT-PCR assays and indicated as fold induction over control (0 h), are shown;
n = 3; p-value b 0.001. E) U937 stable transfected with shRNA CaMKIIγwere cultured 4 days and show an increase of CaMKIV protein expression (n = 3). F) KN93-mediated inhibition of
CaMKII activity results in the elevation of CaMKIV protein in K562 cells . Representative immunoblots showing levels of CaMKIV, p ERK, ERK and Actin (loading control) after treatment
with 10 μM KN93 for indicated time points; (n = 3).
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performed transient transactivation assayswith a CaMK4promoter con-
struct containing RRE, upstream of a ﬁre-ﬂy luciferase reporter gene
[33] and found that RAR-β and COUP-TF conferred an 11-fold
transactivation of the CaMK4 transgene, in the presence of RA (Fig. 2).
However, co-transfection of full-length CaMKII resulted in a signiﬁcant,
2-fold repression of RA/RAR-β/COUP-TF/RA-mediated transactivation
of CaMK4 promoter (Fig. 2). We concluded that CaMKII inhibits
CaMK4 gene expression by repressing its transcription.3.2. Overexpression of CaMKIV in U937 cells inhibits CaMKII activation
CaMKIV is only slightly expressed in U937. To determine if CaMKIV
expression could affect CaMKII expression or activation, we expressed
the full-length CaMKIV using a Lenti-GFP virus system (CaMKIV) [37],
or a Lenti-GFP virus as a control (Mock). Treatment of U937 cells with
the Ca2+ ionophore ionomycin induces the autophosphorylation of
CaMKII (p-CaMKII). This elevation in p-CaMKII levels was blocked
in cells expressing CaMKIV (Fig. 3A). These data suggest that CaMKIV
Fig. 2. CaMKII represses CaMK4 transactivation. CaMKII inhibits RA-dependent
transactivation from RRE of CaMK4 promoter by RAR-β/COUP-TF complexes. Luciferase
activity representing transactivation from CaMK4 promoter, following 48 h of treatment
with 2 μM RA, in the presence of RAR-b, COUP-TF and/or full-length CaMKII is shown.
Data indicated as average (±SD) fold induction over promoter-only constructs from
n = 6 experiments; * p-value b0.0008.
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induced elevation of ERK phosphorylation was repressed in CaMKIV-
U937 cells. Suppression of CaMKII activation by CaMKIV was further
conﬁrmed by in vitro kinase assays using CaMKII immunoprecipitates
from Mock and CaMKIV-U937 cells stimulated with ionomycin
(Fig. 3B). Ionomycin induced activity of CaMKII was signiﬁcantly
inhibited in U937 cells over-expressing CaMKIV. Altogether, these data
indicate that CaMKIV suppresses the autonomous activity of CaMKII in
U937 leukemia cells.
3.3. Increased expression of CaMKIV in U937 cells restricts cell proliferation
CaMKII is a potent stimulator of growth factor-induced cell prolif-
eration in several normal and cancer cells including U937 leukemia
cells [23,26]. As over-expression of CaMKIV suppresses CaMKII activ-
ity, we hypothesized that CaMKIV would inhibit CaMKII-dependent
proliferation of U937 cells. We measured proliferation of CaMKIV-
U937 and Mock-U937 cells in regular growth medium for three
days, and found that the overexpression of CaMKIV in U937 cells
does indeed result in a signiﬁcant retardation of cell growth
(Fig. 4A). To understand whether the retardation of cell growthFig. 3.CaMKIV inhibits CaMKII activity inU937 leukemia cells. A) Expression of CaMKIV inU937
virus (Mock) or Lenti-GFP-CaMKIV virus (CaMKIV) and stimulated with ionomycin (2 μM, 15m
noblot analyses (n= 3). B) CaMKIV effect on CaMKII activation was determined by in vitro kina
stimulated for 15min with 2 μM ionomycin. The activity of immunoprecipitated CaMKII was m
are presented as total incorporated counts per minute (cpm). Average ± SD values from n =induced by CaMKIV was dependent on its kinase activity, we
expressed a kinase-inactive mutant of CaMKIV [38] in U937 cells
and found that this mutant does not affect proliferation (Supplemen-
tary Fig. S2A). This observation suggests that the effect of the overex-
pression of CaMKIV on cell proliferation requires its kinase activity
and is not due to an indirect, non-speciﬁc effect. To determine if
the lack of increase in cell number is due to apoptosis in we tested
Annexin V/propidium iodide (PI) reactivity. As shown in Fig. 4B,
we did not observe any signiﬁcant difference in apoptosis between
CaMKIV- and Mock- U937, either in the presence or the absence
of serum (FBS), indicating that CaMKIV-induced inhibition of prolif-
eration was not secondary to a cell survival defect. On the contrary
the growth retardation observed in CaMKIV-U937 was due to re-
duced cell proliferation, as shown by [3H] thymidine (T) uptake
assay, in Fig. 4C. A similar 2-fold inhibition of [3H] T uptake was ob-
served in Mock-U937 cells treated with either KN-93 or AntCaNtide,
whereas these inhibitors had no effect on [3H] T uptake by CaMKIV-
U937 cells. Taken together, these data support the hypothesis that
CaMKIV expression negatively regulates cell proliferation.3.4. CaMKIV induces G0/G1 cell cycle arrest in U937 leukemia cells
We analyzed the cell cycle proﬁle of U937 cells over-expressing
CaMKIV to determine at which stage of the cell cycle CaMKIV played
its inhibitory role. Flow-cytometric analysis of DNA content showed a
signiﬁcant 3.5-fold increase in the percentage of cells arrested in the
G0/G1 phase in CaMKIV-U937cells. Conversely, the fraction of CaMKIV-
U937 cells in S and G2/M phase was signiﬁcantly decreased (Fig. 5A),
suggesting that over-expression of CaMKIV in myeloid leukemia cells
results in G0/G1 arrest, a feature that is consistent with cell quiescence.
We therefore probed these cells with an antibody against the nuclear
protein Ki-67, which is present in all cycling cells but uniquely absent
in quiescent (G0) cells [39,40]. By combining Ki-67 reactivity with
DNA content analysis (7AAD), we assessed G0, G1 and S-G2-M popula-
tions (Fig. 5B) and found that expression of CaMKIV increases the num-
ber of Ki-67 and 7AAD double negative cells (G0) (Fig. 5Bi and Bii). This
accumulation of CaMKIV-U937 cells in the G0/G1 phase of the cell cycle
requires its kinase activity as expression of a CaMKIV-K71Mmutant did
not elicit a G0/G1 arrest in U937 cells (Supplementary Fig. S2). CaMKIV-
mediated cell cycle arrest was further conﬁrmed through BrdU labeling
combined with 7AAD proﬁle analysis. Thus, a signiﬁcantly lower popu-
lation of CaMKIV-U937 cells entered S-phase of the cell cycle compared
to Mock U937 (Fig. 5Ci and Cii), further indicating that expression of
CaMKIV in U937 cells results in the induction of G0/G1 cell cycle arrest.cells results in the inhibition of CaMKII activation.U937 cellswere infectedwith Lenti-GFP-
in). Levels of CaMKIV, p-CaMKII, total CaMKII, p-ERK and Actin were visualized by immu-
se assays. Endogenous CaMKII was immunoprecipitated fromMock or CaMKIV-U937 cells
easured by in vitro kinase assays using its speciﬁc peptide substrate, Autocamtide. Results
4 experiments are shown. *p-value ≤ 0.05.
Fig. 4. Over-expression of CaMKIV in U937 inhibits cell proliferation. A) Expression of CaMKIV signiﬁcantly restricts U937 cell proliferation. Mock or CaMKIV U937 cells were seeded in
triplicate in 6-well dishes and the total number of viable cells was assessed daily over a period of three days. Average ± SD numbers of viable cells from n = 6 experiments are
shown; p-value b 0.001. B) Expression of CaMKIV in U937 cells does not induce apoptosis. AnnexinV reactivity in Mock and CaMKIV U937 cells was measured during homeostasis and/
or following stimulation with 5% FBS. Data are reported as average ± SD of n = 3 experiments. C) CaMKIV restricts [3H] thymidine incorporation into U937 cells. Mock and CaMKIV
U937 cells were serum starved overnight and treated with vehicle (none), 10 μM KN93 and/or 5 μM AntCaNtide for 30 min. FBS and [3H] thymidine were then added and radioactivity
measured after 24 h by liquid scintillation counting. Average cpm incorporation in cells from n = 3 experiments is shown; p-value b 0.02.
209S. Monaco et al. / Cellular Signalling 27 (2015) 204–2143.5. CaMKIV expression in U937 induces upregulation of Cdk inhibitors
p27kip1and p16ink4a and downregulation of cyclins A, B1 and D
Progression of cells through the G1-S phase of the cell cycle requires
hyper-phosphorylation of the retinoblastoma protein (Rb; p-Rb) by G1
cyclin-Cdk complexes and subsequent activation of the E2F family of
transcription factors [41]. To probe themechanism(s) bywhich CaMKIV
orchestrates G0/G1 arrest in U937 cells, we analyzed the expression
levels of G1-CDKIs. Mock-U937 cells displayed a typical expression pro-
ﬁle of actively proliferating tumor cells, with low levels of p27kip1 and
barely detectable p16ink4a (Fig. 6A, densitometry showed in Supplemen-
tary Fig. S3A). In addition, they possessed markedly elevated p-Rb levels,
both in basal conditions and following FBS stimulation. In contrast, in
CaMKIV-U937 we observed signiﬁcant downregulation of p-Rb in
CaMKIV-U937 cells and an upregulation of p27kip1 and p16ink4a, consis-
tent with a G0/G1 arrest (Fig. 6A and Supplementary Fig. S3A). These
data suggest thatmodulation of G1-CDKIs expression is a keymechanism
by which CaMKIV may suppress U937 cell proliferation.
We further examined the modiﬁcation of cyclin expression in U937
cells. CaMKIV-U937 expressed signiﬁcantly lower levels of cyclin D1
under basal conditions and following stimulation with FBS, which ex-
plains the reduced proliferation and G0/G1 arrest that we observed in
U937 cells over-expressing CaMKIV.
We also evaluated whether over-expression of CaMKIV modu-
lates the expression of cyclins A and B1, which regulate entry of
cells into G2/M phases of the cell cycle in a CaMKII dependent man-
ner [6,7]. In comparison to control, CaMKIV-U937 showed lower
levels of cyclin A in both basal and stimulatory (FBS) media (Fig. 6B
and Supplementary Fig. S3B), suggesting the reduced ability of
these cells to progress through the S-G2 phases of the cell cycle. In-
terestingly, a product of degradation of Cyclin A was detectable
only in CaMKIV-U937 cells, which is consistent with enhanced turn-
over of cyclin A, possibly due to elevated p27kip1 42. Furthermore, the
levels of cyclin B1 after serum stimulation were also decreased in
CaMKIV-U937. (Fig. 6B and Supplementary Fig. S3B), indicating
that CaMKIV could also impair G2-M phases entry (Fig. 6B andSupplementary Fig. S3B). Our data suggest that the expression of
CaMKIV represses cell proliferation by forcing the cells into a G0/G1
arrest via upregulation of CDKIs p27kip1 and p16ink4a.
3.6. CaMKII and CaMKIV expression in primary AML cells and correlation
with the FAB/WHO phenothype
We also studied CaMKIV and CaMKII crosstalk in primary leukemic
BM cells by Western blotting analysis. As shown in Fig. 7A, 4 AML
patients showed increased expression of CaMKIV associatedwith simul-
taneous decreased activity of CaMKII (CaMKIV+/pCaMKII− patients:
10, 14, 9, 17), whereas 10 AML patients showed decreased expression
of CaMKIV associated with simultaneous increase of CaMKII activity
(CaMKIV−/pCaMKII+ patients: 6, 3, 12, 13, 11, 8, 18, 19, 20, 21); we
could not ﬁnd an inverse correlation between CaMKIV expression and
CaMKII activation only in the remaining 7 AML patients (n: 1, 2, 4, 5,
7, 15, 16).
In addition, we documented that all AML patients with the charac-
teristic immature immunophenotype MO/M1 according toWHO classi-
ﬁcation showed increased expression of CaMKIV and decreased
pCaMKII. By contrast, 10/13 AML patients with high differentiation
immunophenotype M4/M5 showed decreased expression of CaMKIV
and increased pCaMKII (CaMKIV−/pCaMKII+). We also performed a
Western blot analysis for pCaMKII and CaMKIV, normalized for CaMKII,
on normal bonemarrow cells as a control (Fig. 7B). Neither pCaMKII nor
CaMKIV were expressed in normal BM samples.
3.7. Inhibition of CaMKII activity elevates CaMKIV expression in primary
monocytes from LMA patients
Since we observed CaMKIV and CaMKII crosstalk in leukemic BM
cells, we also analyzed CAMKIV expression in primary monocytes of
LMA patients following KN93 exposure. Monocytes were isolated from
peripheral blood obtained from LMA-patients. Monocytes were
serum-starved for 1 h and treated with 10 μM of KN93 for 3, 6 and
24 h. CaMKIV and CaMKII expression were analyzed by Western blot.
Fig. 5.CaMKIV induces G0/G1 cell cycle arrest inU937 cells. A) CaMKIVexpression results in the accumulation of U937 cells in theG0/G1 phase of the cell cycle. Propidium iodide (PI) proﬁle
of Mock and CaMKIV U937 cells showing the average (n = 4) percentage of cells in each phase of cell cycle; error bars represent ± SD; *p-value b 0.01. Bi) CaMKIV expression triggers
quiescence in U937 cells. Representative (n = 3) dot plots depicting Ki-67 reactivity versus DNA content (7AAD) analyses in Mock and CaMKIV U937 cells. Bii) Average (±SD) Ki-67/
7AAD double negative cell populations, representing G0 phase of the cell cycle, were calculated from three independent experiments; p-value b 0.001. Ci) CaMKIV restricts entry of
U937 cells into the S phase of cell cycle. Representative (n = 3) histograms depicting BrdU incorporation versus DNA content (7AAD) in Mock and CaMKIV U937 cells. Cii) Boxed
gates representing G0/G1, S and G2/M phases of cell cycle were used to calculate the percentage of cells in the S-phase of the cell cycle in the indicated genotypes. The histograms represent
the % of cells in S phase. Data are reported as average ± SD of n = 3 experiments; p-value b 0.001.
210 S. Monaco et al. / Cellular Signalling 27 (2015) 204–214As shown in Fig. 8 whereas the levels of total CaMKII did not change,
autophosphorylation of CaMKII (p-CaMKII) was signiﬁcantly reduced
following 3 and 6 h of KN93 treatment, and completely inhibited
at 24 h. Of note, low constitutive expression of CaMKIV in primary
monocytes increased as a function of time following exposure to KN93
(Fig. 8).4. Discussion
The present study is the ﬁrst demonstration of the reciprocal role
of CaMKII and CaMKIV on cell proliferation in cancer cells. We dem-
onstrated that CaMKII activation in leukemia blasts inhibits CaMKIV
expression. A role for CaMKII in the regulation of proliferation and
Fig. 6. CaMKIV over-expression triggers the upregulation of CDKIs p16ink4a and p27kip1 and a concomitant downregulation of cyclins D1, A and B1 in U937 cells. A) CaMKIV expression in
U937 cells leads to signiﬁcantly enhanced p16 ink4a and p27kip1levels and a concurrent inhibition of Rb phosphorylation. Immunoblots depicting p16 ink4a, p27kip1, p-Rb and Actin inMock
and CaMKIV U937 cells, during homeostasis and following FBS stimulation are shown. B) Forced expression of CaMKIV results in decreased levels of cyclins D1, A and B1; and in the pro-
teolytic cleavage of cyclin A. Cell lysates fromMock and CaMKIV U937 cells were subjected to immunoblot analyses with antibodies against cyclins D1, E, A and B1. Positions of full-length
(60 kDa) and cleavage intermediates (38 kDa and 40 kDa) of cyclin A are indicated.
Fig. 7. Cross-regulatory relationship between CaMKII and CaMKIV in primary acutemyeloid leukemia (AML) cells. A) Bonemarrow sampleswere obtained, after informed consent, during
diagnostic procedures from 21 patients with AML. Collected speciemenswere analyzed byWestern blotting to evaluate CaMKII activation and CaMKIV expression. 4 AML patients showed
increased expression of CaMKIV associated with simultaneous decreased activity of CaMKII, whereas 10 AML patients showed decreased expression of CaMKIV associated with simulta-
neous increase of CaMKII. B) Samples of normal bone marrow were analysed by Western blot for pCaMKII, CaMKII and CaMKIV.
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Fig. 8. Pharmacological inhibition of CaMKII induces the expression of CaMKIV in
primary monocytes. KN93-mediated inhibition of CaMKII activity results in the increase
of CaMKIV protein. Representative immunoblots showing levels of CaMKIV, pT286CaMKII
(p-CaMKII), total CaMKII and Actin (loading control) in primary monocytes isolated
from peripheral blood of LMA-patients, treatedwith 10 μMKN93 for indicated time points
(n = 3).
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7,22,25]. One of the mechanisms by which CaMKII stimulates
growth factor-induced cell proliferation is the activation of the
ERK pathway [20,43]. It has been reported that activation of CaMKII
is essential for cell proliferation by facilitating G1-S, G2-M andmeta-
phase to anaphase transitions [3,6,44,45]. In contrast, CaMKIV can
restrict aberrant proliferation and promote survival of hematopoi-
etic cells by activating the CREB/Bcl2 pathway [12,46]. However, a
cross-talk between these two multifunctional CaMKs in the modu-
lation of cell physiology has never been reported. In the present
study we demonstrate a novel interplay between CaMKII and
CaMKIV, which could have implications in the control of leukemia
cell proliferation.
Under resting conditions, the human leukemicmonocyte lymphoma
U937 cells express high levels of CaMKII and very low, barely detectable,
levels of CaMKIV. We provide evidences that CaMKII inhibits CaMKIVFig. 9. Cross regulatory relationship between CaMKII and CaMKIV in the regulation of leukemi
barely detectable. CaMKII suppresses CaMKIV transcriptionwhereas CaMKIV over-expression p
have shown that CaMKII regulates the half-life of p27kip1 by mediating its degradation via th
CaMKIV inhibits the proteasome-mediated degradation of p27kip1 via the CAMKII-Erk pathway
ylation and E2F activation. As a consequence, cell cycle progression is blocked. In this case, CaM
cells elevates p16ink4a and represses cyclin A levels through unknownmechanisms and elicits c
oppose each other in the regulation of myeloid leukemia cell proliferation, with CaMKII promogene expression by repressing RAR-induced activation of the CaMK4
promoter. Pharmacological inhibition of CaMKII de-represses the
CaMK4 promoter to enhance CaMKIV mRNA and protein expression in
two different cell lines: U937 and K562. We also demonstrated that
the pharmacological inhibition of CaMKII by KN93 in primary mono-
cytes, increases the levels of CaMKIV as a function of time (Fig. 8). It
has been demonstrated that in several hematopoietic cell lines the
expression of CaMKIIγ negatively correlates with the expression of
CaMKIV. Whether this counterregulation is casual or mechanistic has
been never investigated. We show that forced expression of CaMKIV
in U937 cells suppresses CaMKII activity and its pro-proliferation func-
tion. Speciﬁcally, CaMKIV overexpression induces G0/G1 cell cycle arrest
in U937 cells, through upregulation of CDKIs p27kip1 and p16ink4a and
downregulation of G1 and G2/M cyclins. These ﬁndings suggest that, in
U937 leukemia cells, CaMKII is a positive regulator of cell proliferation,
whereas CaMKIV plays an opposite role, inhibiting cell cycle progression.
Cell cycle arrest subsequent to pharmacological inhibition of CaMKII
by KN93 has been reported in several myeloid leukemia cell lines, in-
cluding U937, and in primary AML patient samples [26,47]. Moreover,
CaMKII levels become markedly reduced in leukemia cells undergoing
growth arrest and/or terminal differentiation [47]. Results from our
study are consistent with these previous ﬁndings. Further, they provide
additional evidence that the block in cell cycle progression in U937 cells
following pharmacological inhibition of CaMKII is, at least in part, due
to the re-expression of CaMKIV, which promotes a cell cycle arrest in
G0/G1.
CaMKIV induced the expression of p16ink4a, which plays a pivotal
role in cell cycle progression at the G1-S checkpoint. Rb and p16ink4a
acts in a common pathway, where hyper-phosphorylation of Rb results
in the activation of E2F, leading to the expression of cyclin D1, cdc2 and
cyclin A. Rb is a tumor suppressor [48] that is associated with the eleva-
tion of p16 ink4a in different cell models [49–51], which is compromised
in senescent ﬁbroblasts and several cancers [51,52]. CaMKIV-mediated
enhancement of p16ink4a and subsequent downregulation of cyclin D1
results in G1 cell cycle arrest. Further, CaMKIV expression elevates
p27kip1 in U937 cells. Previous reports have demonstrated that CaMKIIa cell proliferation. In U937 cells CaMKII is expressed at very high levels while CaMKIV is
romotes the inhibition of CaMKII autonomous activity and cell cycle arrest. Previous studies
e Mek/Erk pathway [43]. Therefore, we hypothesize that by suppressing CaMKII activity,
. Stabilized p27kip1 will then inhibit Cdk4/cyclinD1 complexes, and therefore Rb phosphor-
KIV promotes cell cycle arrest (solid gray arrow). Further, expression of CaMKIV in U937
ell cycle arrest (denoted by the dashed gray arrow). We conclude that CaMKIV and CaMKII
ting proliferation and CaMKIV promoting quiescence.
213S. Monaco et al. / Cellular Signalling 27 (2015) 204–214is a negative regulator of p27kip1, mainly through its activation of the
ERK pathway and subsequent proteolytic degradation of p27kip143.
Thus CaMKIV may cause the upregulation of p27kip1 in U937 leukemia
cells, indirectly, through its suppression of CaMKII activity (Fig. 6).
Levels of cyclins A, B and D1 were considerably lower in CaMKIV-
U937 cells and cyclin A appeared to be proteolytically cleaved. Previous
reports suggest that p27kip1 elicits the proteolytic cleavage of cyclin A
within its N-terminal domain to form products that lack mitotic activi-
ty [42]. In dividing myeloid progenitor cells, this cleavage of cyclin A is
important for the onset of differentiation [53]. The correlation between
CaMKIV expression and the appearance of the A38/40 cyclin A fragment
is therefore not surprising, as CaMKIVmodulates the differentiation of a
number of cell types, including neurons, osteoclasts, and dendritic cells
[12,27,28,46,54].
Of note, we found a similar regulatory cross-talk between CaMKII
and CaMKIV in primary AML cells. Indeed, CaMKII activation was
associatedwith CaMKIV down-regulation and, conversely, CaMKIV over-
expression with increased CaMKII activation. Moreover, pCaMKII activa-
tion mediating concurrent CaMKIV downregulation was associated with
differentiated M4/M5 AML phenotype, whereas pCaMKII inhibition me-
diated by CaMKIV upregulation was associated with immature M0/M1
AML phenotype.
This inverse correlation between CaMKIV and CaMKII activation,
although assessed in a limited number of samples, suggests a cross reg-
ulatory relationship between CaMKII and CaMKIV in the regulation of
leukemia cell proliferation and/or differentiation. In these cells, CaMKII
represses the expression of CaMKIV. In contrast, overexpression of
CaMKIV exerts a negative regulation on CaMKII activation that results
in inhibition of the MAPK pathway and cell cycle arrest (Fig. 9).
Although larger studies are needed to identify the mechanisms of
the crosstalk between CaMKII and CaMKIV in primary AML cells, and
demonstrate the existence of a correlation between pCaMKII/CaMKIV
ratio and FAB, our ﬁndings suggest that CaMKII and CaMKIV might
have opposite roles in transformed leukemia cells and that the balance
of their expression and activities can regulate not only cell proliferation,
but also drive their differentiation.
The focus of our paper is the reciprocal regulation of CaMKII
and CaMKIV as a general feature for cellular proliferation and survival.
Indeed, the cellular process we describe in the manuscript is a widely
diffuse feature, present in, but not restricted to, AML. Indeed, we ana-
lyzed two leukemia cell lines (U937 andK562) and a number of primary
AMLs, and in these models we conﬁrm the existence of such regulatory
mechanism, even despite different patterns of oncogene expression. In
particular, K562 cells are bcr-abl positive, while U937 are not. We also
have some experimental data (paper in submission) that this regulation
between CaMKII and CaMKIV occurs also in solid tumors and in partic-
ular in cancer cell lines such as KAT-4 and HT-29. Thyrosine kinase
inhibitors, targeting proteins such as BCR-ABL, VEGFR, and Raf are
currently used in the therapy of several tumors including leukemia
[55,56], The interplay between CaMKII and CaMKIV could allow the
identiﬁcation of novel therapeutic targets in the same pathways to
exploit in the treatment of myeloproliferative disorders.
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